Feed additives from Huvepharma and DSM get EFSA stamp of approval
The Parma-based assessor has backed Huvepharma’s additive, Coxiril, for the control of coccidiosis in turkeys for fattening at the dose of 1.2 mg diclazuril per kilogram of feed.
Coxiril, containing 0.5 % diclazuril, is considered toxicologically equivalent to currently authorized products containing diclazuril as the specifications of the European Pharmacopoeia are respected, said EFSA.
The agency’s Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) said: “A residue study with Coxiril in turkeys for fattening demonstrated compliance with the maximum residue limits for diclazuril without applying a withdrawal period.”
The opinion can be read here.
DSM wins approval for its synthetic astaxanthin
The FEEDAP Panel also issued a positive opinion in its re-evaluation of the safety of DSM’s synthetic astaxanthin product, Carophyll Pink, for salmonids.
It concluded that synthetic astaxanthin is safe for salmonids up to 100 mg per kg of diet.
The EFSA team found astaxanthin is efficacious in coloring the flesh of salmonids, while the use of the additive for salmon and trout is of no concern for the safety of the consumer.
They also found the use of synthetic astaxanthin does not pose a significant additional risk to the environment compared with natural astaxanthin.
The opinion can be read here.
GM oilseed rape backed by EU assessor
EFSA has also authorized Monsanto’s MON 88302 oilseed rape crop in terms of safety. MON 88302 has been genetically modified to be tolerant of herbicides.
EFSA’s Panel on Genetically Modified Organisms (GMO) delivered its positive scientific opinion on the application to place the MON 88302 crop on the European market for food and feed uses, import and processing.
“Based on the agronomic and phenotypic characteristics of oilseed rape MON 88302 tested under field conditions, no biologically relevant differences were observed between oilseed rape MON 88302 and its conventional counterpart, except for days-to-first flowering.
The observed difference for days-to-first flowering could be attributed either to the variability in the genetic background of the Ebony population or to an unintended effect due to the genetic transformation process,” said the EFSA opinion.
“No differences in the compositional data of seeds obtained from oilseed rape MON 88302 requiring further assessment with regard to safety by the EFSA GMO Panel were identified.”
The GMO Panel concluded that it “considers that the information available addresses the scientific requirements of the EFSA GMO Panel and the scientific comments raised by the Member States, and that oilseed rape MON 88302, as described in this application, is as safe as its conventional counterpart and non-GM commercial oilseed rape varieties with respect to potential effects on human and animal health and the environment in the context of the scope of this application.”
The opinion can be read here.
